Cognitive impairment is frequent in patient with Parkinson's disease (PD), and can range from mild deterioration to dementia. Recently a contribution of Alzheimer's disease for the cognitive dysfunction in PD has been proposed, whereas the presence of tau protein and amyloid was recognized. Clusterin/ApoJ is a protein involved in the deposition of beta- amyloid and in its neurotoxicity. In this study we aimed to investigate the clusterin/Apoj's plasma levels in patients with PD to assess its potential role in fisiopathogenetic cognitive impairment.
Correlation between cognitive impairment and plasma levels of clusterin/ApoJ in Parkinson disease patients not affected by dementia.
RUBINI, Giuseppe;POLIMENO, Lorenzo;DE CARO, Maria;
2013-01-01
Abstract
Cognitive impairment is frequent in patient with Parkinson's disease (PD), and can range from mild deterioration to dementia. Recently a contribution of Alzheimer's disease for the cognitive dysfunction in PD has been proposed, whereas the presence of tau protein and amyloid was recognized. Clusterin/ApoJ is a protein involved in the deposition of beta- amyloid and in its neurotoxicity. In this study we aimed to investigate the clusterin/Apoj's plasma levels in patients with PD to assess its potential role in fisiopathogenetic cognitive impairment.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
